Athena Heart 310 Info

The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets ATHENA HEART 310

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. The therapy is being tested for those with

Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: By "turning off" this gene, the body can

Targeted protein levels decreased by an average of 73%.

Mean reductions of ~49%, with peak effects reaching 87% .

Detailed clinical summaries and press releases are available directly from CRISPR Therapeutics and medical news sources like Drug Discovery News . If you'd like to dive deeper into the research: